The University of Oxford has launched the first human trial of a vaccine against Bundibugyo ebolavirus, seeking to accelerate efforts to combat an outbreak spreading in the Democratic Republic of Congo and Uganda.
Vaccine Development
The early-stage trial, known as BD-Ebov, will evaluate the safety and immune response of the ChAdOx1 BDBV vaccine in 50 healthy adults aged 18 to 55 in Oxford.
The vaccine was developed by scientists at Oxford’s Vaccine Group and Pandemic Sciences Institute using the same viral vector platform as the Oxford/AstraZeneca COVID-19 shot.
Preparations are also under way for additional clinical studies in Uganda, subject to regulatory approval, through partnerships including the Medical Research Council/Uganda Virus Research Institute and the London School of Hygiene and Tropical Medicine Uganda Research Unit.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
